Cyclic adenosine 3 0 5 0 monophosphate (cAMP) and protein kinase A (PKA) cooperate with phosphatidylinositol 3 0 kinase (PI3K) signals in the control of growth and survival. To determine the molecular mechanism(s) involved, we identified and mutagenized a specific serine (residue 83) in p85a
Cyclic adenosine 3 0 5 0 monophosphate (cAMP) and protein kinase A (PKA) cooperate with phosphatidylinositol 3 0 kinase (PI3K) signals in the control of growth and survival. To determine the molecular mechanism(s) involved, we identified and mutagenized a specific serine (residue 83) in p85a PI3K , which is phosphorylated in vivo and in vitro by PKA. Expression of p85a PI3K mutants (alanine or aspartic substitutions) significantly altered the biological responses of the cells to cAMP. cAMP protection from anoikis was reduced in cells expressing the alanine version p85a PI3K . These cells did not arrest in G1 in the presence of cAMP, whereas cells expressing the aspartic mutant p85D accumulated in G1 even in the absence of cAMP. S phase was still efficiently inhibited by cAMP in cells expressing both mutants. The binding of PI3K to Ras p21 was greatly reduced in cells expressing p85A in the presence or absence of cAMP. Conversely, expression of the aspartic mutant stimulated robustly the binding of PI3K to p21 Ras in the presence of cAMP. Mutation in the Ser 83 inhibited cAMP, but not PDGF stimulation of PI3K. Conversely, the p85D aspartic mutant amplified cAMP stimulation of PI3K activity. Phosphorylation of Ser 83 by cAMP-PKA in p85a PI3K was also necessary for estrogen signaling as expression of p85A or p85D mutants inhibited or amplified, respectively, the binding of estrogen receptor to p85a and AKT phosphorylation induced by estrogens. The data presented indicate that: (1) phosphorylation of Ser 83 in p85a PI3K is critical for cAMP-PKA induced G1 arrest and survival in mouse 3T3 fibroblasts; (2) this site is necessary forIntroduction Cyclic adenosine 3 0 5 0 monophosphate (cAMP) regulates the growth of many cells types (Pastan et al., 1975) . Although cAMP can promote the growth of some cells, such as Swiss 3T3 fibroblasts and thyrocytes (Lee et al., 1998; Ariga et al., 2000) , it inhibits proliferation in most cells (Magnaldo et al., 1989) . However, the precise mechanism by which cAMP inhibits cell cycle entry and progression remains undefined (Houslay and Kolch, 2000) . cAMP prevents cells from entering S phase and arrests the cells in G1 (Kato et al., 1994) . Furthermore, cAMP inhibits proliferation stimulated by either G protein-coupled receptors or receptor tyrosine kinases (Magnaldo et al., 1989) , suggesting that it targets a signaling pathway that is central to cell cycle progression.
Stimulation of growth by cAMP-protein kinase A (PKA) in selected cell types, as thyroid cells, is tightly dependent on Ras and phosphatidylinositol 3 0 kinase (PI3K) (Ciullo et al., 2001) . Also, cAMP and PKA are powerful survival signals in several cell types (Affaitati et al., 2003) . To date the mechanism(s) and the relevant players mediating cAMP effects on growth and survival are not completely known.
We have previously shown that cAMP and PKA regulate Ras signaling, by selectively stimulating Ras-PI3K complex. Also, we have found that p85a PI3K was an efficient PKA substrate in vitro (Ciullo et al., 2001 ).
Here we report that Ser 83 in the p85a PI3K is phosphorylated in vivo by PKA and that the corresponding mutants (p85A or p85D) inhibit or amplify cAMP biological effects on growth and survival. This site is also relevant for the interaction of p85a PI3K with estrogen receptor a, as the mutants inhibit or amplify estrogen signaling to PI3K. Finally, we demonstrate that cAMP in the absence of serum stimulates PI3K and that p85a PI3K mutants selectively interfere with cAMP stimulation of PI3K activity.
These data provide a molecular framework that explains the synergism between cAMP and different types of receptors, and add another level of complexity to the regulation of PI3K and Ras p21 by cAMP-PKA.
Results

PKA phosphorylates Ser 83 in p85a PI3K
p85a subunit of PI3K can be efficiently phosphorylated by PKA in vitro (Ciullo et al., 2001) . A possible PKA target sequence is Ser 83, which is highly conserved in evolution and is preceded by basic residues in bovine/human (KKIS) and mouse/rat (KRIS) sequences.
To determine the relevance of this site in vivo, we have substituted Ser 83 with alanine (p85A) to prevent phosphorylation or with aspartic acid (p85D) to mimic the phosphorylated residue. The tagged recombinant proteins were transiently expressed in HeLa or NIH3T3 cells and immunoprecipitated with anti-flag antibody.
Immunoprecipitates were incubated in vitro with purified catalytic PKA subunit in the presence of [ 32 g-P]ATP. p85a PI3K wild type was efficiently phosphorylated by PKA whereas p85A was not, indicating that Ser 83 was the site phosphorylated by PKA in vitro ( Figure 1a ). PKA-phosphorylated p85a PI3K was also identified in vivo in breast cancer cells MCF7 extracts immunoblotted with an antiphosphoserine antibody. Figure 1b shows that p85a PI3K , not p85A, was recognized by the phosphoserine antibody in extracts of MCF7 cells treated with cAMP. Figure 1c shows the same experiment performed in NIH3T3 cells expressing p85a PI3K and p85A. The p85A protein was not recognized by the antiphosphoserine antibody. Phosphorylation of p85a PI3K was prevented by incubating the cells with the PKA kinase inhibitor H89 (Figure 1c ). The endogenous protein p85a
PI3K was also phosphorylated in NIH3T3 cells stimulated with cAMP. Phosphorylation was inhibited by pretreating the cells with H89 ( Figure 1d ). Taken , we determined in mouse fibroblasts the rate of anoikis, a specific apoptotic pathway triggered by loss of cell adhesion to the extracellular matrix (Frisch and Francis, 1994; Khwaja et al., 1997) . We cotransfected NIH3T3 cells with a GFP encoding vector and the wild type or the mutant versions of p85a PI3K (Figure 2a and b) . At 48 h after transfection, the cells were plated on 2% agarose in a medium containing 0.1% calf serum in presence or absence of 200 mM cAMP. After 5 h, we determined the fraction of apoptotic cells by fluorescent activated cell sorter (FACS) analysis. Figure 2b shows that treatment with cAMP significantly reduced the number of apoptotic cells. cAMP cytoprotection was abolished by wortmannin, a PI3K inhibitor (data not shown and Khwaja et al., 1997) . Expression of wild-type p85a PI3K amplified cAMP response (see n in Figure 2b ), whereas expression of p85A completely eliminated cAMP amplification, displayed by wild-type p85a PI3K (Figure 2b ). Cells expressing p85D, on the other hand, were significantly more resistant to anoikis in the absence of cAMP (see nn in Figure 2b ). The low response to cAMP of these cells was probably dependent on the low levels of p85D protein (Figure 2a ). These data indicate that p85a To test if p85a PI3K mediated also cAMP inhibition of growth in mouse NIH3T3 fibroblasts, we analysed the biological effects of p85a PI3K mutants on growth arrest induced by cAMP. NIH3T3 fibroblasts were cultured in low serum in the presence or absence of cAMP. Under these conditions, cAMP induced a robust and reversible inhibition of cell growth by accumulating the cells in G1 phase and reducing the fraction of cells entering S phase (see n in Figure 2c and d). Cells expressing p85A did not efficiently arrest in G1 in the presence of cAMP ( Figure 2c ). Conversely, in cell lines expressing the aspartic mutant, cAMP response was lost and the fraction of cells accumulating in G1 was significantly higher than in cells expressing p85A (see nn in Figure 2c ). The fraction of cells arrested in S phase in the presence of cAMP was robustly stimulated in the control and cells expressing the wild-type p85a PI3K (see n in Figure 2d ). Cells expressing the mutant versions of p85a PI3K did not respond to cAMP and the fraction of cells transiting S increased (see Figure 2d , p85Annn) or decreased (see Figure 2d , p85Dnnn) relative to control or wild-type p85a PI3K cells. These data indicate a higher (p85D) or lower rate of G1 arrest (p85A) of these cell lines, independently on cAMP presence in the medium. The high statistical significance of S phase values, relative to G1, is due to the lower value of S phase cell fraction. To discriminate more precisely the effects of cAMP in G1 or S phases in cells expressing p85a PI3K mutants, we performed a kinetic analysis of the cell cycle by labeling the cells with BrdU. Under these conditions, the entry and the progression in S phase of transfected cells can be precisely determined. Figure 2e shows that p85A or p85D did not alter S phase progression, cAMP, estrogen, PI3K and Ras signalling C Cosentino et al although p85A-expressing cells transited S phase very rapidly, compared to control or p85D expressing lines in the presence of cAMP. Cells expressing p85A were unrestrained in G1 in the presence of cAMP and entered S phase more efficiently than control or p85D-expressing cells. Taken together, these data indicate that Ser 83 in the p85a PI3K is critical for cAMP-induced G1 arrest on cell cycle progression. Alanine substitution of Ser 83 abolished G1 arrest by cAMP. p85D, on the other hand, increased the number of cells arrested in G1 in the absence of cAMP (see nn in Figure 2d ).
p85a
PI3K (ser83) phosphorylation increases association of to p21 Ras We have previously shown that cAMP PKA selectively increased the association between PI3K and p21 Ras (Ciullo et al., 2001) . As this complex can mediate cAMP-PI3K effects on growth and survival, we set out to determine the formation of p21 Ras-PI3K complex in cells expressing wild-type p85a PI3K or p85A or p85D. NIH3T3 were transfected with p85a PI3K wild type or p85A or p85D and 36 h after transfection, the cells were serum starved for 16 h before 10 min treatment with cAMP. Cell lysates were immunoprecipitated with antiflag antibody and then analysed by Western blot with anti-Ras antibody. In the presence of cAMP, p85a PI3K wild type efficiently was found associated with p21 Ras. This association was significantly inhibited in cells expressing p85A and stimulated in p85D expressing cells. In the absence of cAMP, Ras-PI3K complex was barely detectable in all the samples. In p85D-expressing cells, however, cAMP stimulated robustly association of PI3K to p21 Ras, suggesting that Ser 83 in p85a PI3K cooperates with another cAMP-PKA signal to regulate PI3K association with p21 Ras (Figure 3a and b) . We also tested the effects of H89 on the formation of the Ras-PI3K complex. H89 treatment reduced the complex Ras-PI3K to the levels found in p85A-expressing cells (Figure 3c ). These data indicate that under conditions of cAMP stimulation, the interaction Ras-PI3K is significantly favored.
PI3K (Ser 83) phosphorylation selectively amplifies PI3K signaling by cAMP To directly test the hypothesis that cAMP stimulation amplified Ras-PI3K signalling, we stimulated the cells with cAMP or PDGF and determined AKT and GSK phosphorylation, downstream targets of PI3K. Figure 4a shows that cAMP and PKA stimulated the phosphorylation of AKT and GSKa and that H89 reversed cAMP effects. To test if p85a PI3K mutants interfere also with other pathways that signal to PI3K, we determined PDGF stimulation of AKT and ERK1/2, the two major kinases downstream to PDGFR. Figure 4b shows that expression of p85A and p85D did not significantly influence PDGF stimulation of ERK1/2 or P-AKT accumulation. p85A-expressing cells, on the other hand, poorly phosphorylated AKT or GSKa in response to cAMP. Conversely, expression of p85D increased the basal P-AKT and P-GSKa and robustly amplified cAMP response (Figure 4c and d) .
So far we have analysed the effects of p85a PI3K variants on indirect effectors of PI3K signaling. To directly test the relevance of cAMP induced phosphorylation of p85a PI3K on PI3K activity, we have measured the activity of the enzyme in cells expressing wild type or the mutant versions of p85a PI3K . We have previously reported that cAMP in the presence of serum did not stimulate PI3K activity (Ciullo et al., 2001) . As the presence of serum can mask some important biological effects of cAMP-PKA (Porcellini et al., 2003) and (De Gregorio et al., 2006, in Figure 5 shows that cAMP stimulated PI3K activity. The activation of PI3K was inhibited by treatment of the cells with the PKA inhibitor, H89. Moreover, cells expressing p85A did not activate PI3K in response to cAMP, whereas efficiently activated PI3K, when treated with PDGF. Conversely, p85D amplified PI3K activity induced by cAMP and did not significantly influence PI3K stimulated by PDGF ( Figure 5 , lower inset).
To determine if p85A altered the structure of the protein and inhibited the formation of the PI3K complex, we tested the ability of in vitro synthesized p85a PI3K to interact and form a stable complex with p110a PI3K . Supplementary Figure 1S shows that cotranslated p85a PI3K and p110a PI3K interact very efficiently. When tested under the same conditions, p85A ability to interact with p110a PI3K was comparable to that of the wild-type p85a PI3K (Supplementary Figure 1S) . p85D, on the other hand, formed a complex with p110a PI3K synthesized in vitro, with a higher affinity than p85a PI3K wild type or p85A. These data indicate that p85A does not disrupt the folding of p85a PI3K protein or the ability to interact with p110a PI3K , whereas p85D induces a conformational change that improves the interaction with p110a PI3K . As p85D stimulates cAMP-induced PI3K activity, we suggest that this conformational change activating the enzyme is mediated by phosphorylation of p85a PI3K in Ser 83 by PKA.
cAMP-PKA amplify estrogen binding and signaling to PI3K PI3K mediates also AKT activation by estrogens (Simoncini et al., 2000; Castoria et al., 2001) . As p85a PI3K was efficiently phosphorylated by PKA in MCF7, the breast carcinoma cell line, we asked whether p85a PI3K phosphorylation on Ser 83 also affected PI3K interaction with upstream effectors such as estrogen receptor. Therefore, we analysed the phosphorylation of AKT stimulated by estrogen. Cells expressing p85a PI3K wild type or p85A or p85D were treated with estrogens and stimulation of AKT was monitored with specific P-AKT antibodies. Figure 6a shows that p85D amplified AKT phosphorylation induced by estrogens and that p85A abolished this stimulation. Also, induction of GSK phosphorylation by estrogens was inhibited by p85A expression (data not shown).
As estrogen stimulation of AKT was inhibited in cells expressing p85A, we measured the fraction of the estrogen receptor a bound to wild type and mutant versions of p85a
PI3K
. Figure 6b shows that wild-type p85a PI3K immunoprecipitated efficiently the receptor. The binding of estrogen receptor to p85a PI3K was stimulated by estrogens, as expected. cAMP did not stimulate the binding per se in the absence of estrogens, but amplified the action of estrogens on p85a PI3K binding. H89, a PKA inhibitor, eliminated the binding of the receptor to p85a PI3K . The p85A protein did not bind the estrogen receptor in the presence or in the absence of estrogens. Expression of p85D substituted . H89 inhibited the binding of p85D to estrogen receptor, indicating that another phosphorylation PKA-dependent was necessary for the formation of the complex estrogen-p85a PI3K . These data indicate that phosphorylation by cAMP-PKA of Ser 83 in p85a PI3K is required for estrogen binding and signalling to PI3K.
Discussion
The data presented here indicate that the phosphorylation of p85a PI3K in a critical serine residue mediates cAMP action on growth and survival. More specifically, phosphorylation of Ser 83 in p85a PI3K shifts the signaling flow towards PI3K-driven pathways. Such a conclusion is supported by several observations. The substitution of Ser 83 with alanine inhibited cAMP effects on cell survival and G1 arrest in NIH 3T3 fibroblasts. Conversely, the aspartic mutant of Ser 83 in p85a PI3K stimulated cell survival in the absence of cAMP and slowed down cell cycle cycle progression, replicating the effects of cAMP. Ras binding to PI3K and AKT phosphorylation were inhibited by expressing p85A and were stimulated by p85D.
cAMP effects on growth and cell cycle progression are very selective. cAMP-PKA act on at least three phases Figure 5 cAMP stimulates PI3K activity in the absence of serum. Effects of p85a PI3K mutants on PI3K catalytic activity. NIH3T3 cells were transfected with the p85a PI3K expression vectors indicated and stimulated with cAMP (100 mM) 20 min in the presence or absence of H89 (10 mM) or PDGF (100 ng/ml) 15 min, 48 h after transfection. Total extracts were prepared and subjected to immunoprecipitation with anti-flag antibody. Immunoprecipitates were quantified by immunoblot with anti-p85a PI3K antibodies (p85a PI3K -flag) and assayed for PI3K activity by using a mixture of lipids containing PI4-5 (see Materials and methods). PI-4-5 labeled at position 3 is indicated by the arrow. The upper inset (a) shows PI3K activity associated with p85a PI3K -flag wild type and the immunoblot with anti-p85a PI3K antibody of the p85a PI3K -flag immunoprecipitate. The lower inset (b) shows PI3K activity associated with p85A and p85D, immunoprecipitated with the anti-flag antibody. The immunoblot with the p85a PI3K antibody is shown below. The histograms on the right show the statistical analysis of (a) and (b) derived from three experiments.
cAMP, estrogen, PI3K and Ras signalling C Cosentino et al of cell cycle. cAMP slows down G1, blocks S phase and G2-M transition (Kato et al., 1994; Kurokawa and Kato, 1998; Houslay and Kolch, 2000) . Our data indicate that p85a PI3K phosphorylation of Ser 83 controls selectively G1-S transition (Figure 2) .
PI3K is an important regulator of cell growth as it links cell size, growth and cycle progression. For example, constitutive expression of p110a increases cell mass and size by stimulating the biosynthetic capacity of the cells. However, if not restrained, p110 activity impairs exit from the cell cycle (Alvarez et al., 2003) . We suggest that Ras-PI3K signals regulate the length of G1 phase. cAMP by amplifying and stabilizing PI3K, lengthens G1 and slows down G1-S transition. The net result is an apparent G1-S block, which results in increased biosynthetic activity and cell mass prior to division. This is better shown in thyroid cells, FRTL5, which are exquisitely dependent on TSH and cAMP for growth and differentiation. In these cells, Ras and PI3K are selectively required for G1 phase progression (Ciullo et al., 2001) . In thyroid cells, TSH induces PI3K activity and stabilizes the complex Ras-PI3K. Also, expression of p85 mutant (p85A) inhibits selectively the stimulation of growth and PI3K activity induced by TSH (De Gregorio et al., in press). In thyroid cells and in cells expressing high levels of the regulatory subunit of PKA, RIIb, p85a PI3K binds and anchors PKA. This binding is amplified in cells expressing p85D and it is H89 resistant (De Gregorio et al., in press ). This suggests that anchoring PKA to the membrane is a prerequisite for cAMP-PKA biological effects.
Also, cAMP-PKA stimulate in the absence (Figure 5) , not in the presence of serum (Ciullo et al., 2001) Although the cell lines we have used are not robustly dependent on cAMP signaling for growth or differentiation, our data indicate that PI3K-Ras signals are amplified by cAMP both in cAMP-independent (NIH3T3 fibroblasts or breast MCF7 cells) or dependent (thyroid) cells. In these latter cells, amplification of PI3K by cAMP is mainly triggered by TSH and PKA, which binds p85a
PI3K
. The amplification of the pathway Ras-PI3K induced by cAMP is redundant in 3T3, but not in thyroid cells, because in these latter cells expression of p85A triggers apoptosis (De Gregorio et al., in press) .
We suggest that Ser 83 in p85a PI3K is an important point of convergence of two parallel pathways: cAMP-PKA and PI3K signals. In this framework, it is worth noting that in Saccharomyces cerevisiae inactivation of PI3K-TOR signalling is partly compensated by iper-activation of cAMP-PKA (Rohde et al., 2004; Zurita-Martinez and Cardenas, 2005) .
Our data indicate that estrogen receptor signalling was profoundly altered when p85A was expressed. Accordingly, p85a PI3K binding to estrogen receptor was severely impaired. Although PKA phosphorylates directly AKT and estrogen receptor (Cui et al., 2004) , the effects we described were mainly dependent on p85a PI3K , as they were inhibited or amplified by expressing the p85a PI3K alanine or aspartic mutants, respectively. Moreover, we have data indicating that also induction of estrogen responsive genes is inhibited by H89 and it is significantly altered in p85A-expressing cells (data not shown). Estrogens stimulate adenylyl cyclase (Aronica et al., 1994) and cAMP-PKA stimulate differentiation of granulosa cells (Knecht et al., 1984) . Our data indicate that phosphorylation of Ser 83 in p85a PI3K by cAMP PKA stabilizes the binding of activated receptor to PI3K and stimulates PI3K activity.
General implications
The data presented above have broad implications because they point to p85a
PI3K as the physical link between Ras, estrogen receptor and cAMP-PKA (Figure 7) . Also, we find in many and unrelated cell types that cAMP amplification of PI3K is essential for negative or positive cAMP effects on growth and survival. Apparently, all receptors binding p85a PI3K can cooperate with cAMP-PKA signals via phosphorylation of Ser 83 in p85a
PI3K . This may explain the pleiotropic nature of the effects exerted by cAMP-PKA on several, apparently unrelated, signaling cascades and illustrates how cAMP-PKA can influence Ras p21 effectors at multiple levels.
Materials and methods
Plasmid construction
The cDNA encoding for p85a PI3K -flag wild type was generated by fusing the flag sequence (MDYKDDDDK) to the C- -flag was then used as template for site-directed mutagenesis (QuickChange Site-Directed Mutagenesis Kit, Stratagene) to convert Ser 83 in alanine or aspartic acid. All the plasmid constructs were verified by DNA sequence analysis.
Cell culture and transfections
HeLa and NIH3T3 cells were grown in RPMI with 10% fetal calf serum or Dulbecco's modified Eagle's medium (DMEM) with 10% calf serum, respectively. MCF-7 cells were grown in DMEM with 5% fetal bovine serum, supplemented with: penicillin/streptomycin 100mU/ml, 2 mM glutamine, 6 ng/ml insulin and 3.75 ng/ml hydrocortisone. Cells were transfected with lipofectamine (Gibco-Invitrogen, Carlsbad, CA, USA). In all transfections, RSV-LacZ was included to determine and normalize transfection efficiency. Experiments varying in the transfection efficiency above 20% were discarded.
Antibodies, immunoprecipitation and immunoblot
The antibodies used were: anti-Ras (mouse monoclonal panRas clone 10, UBI (an affiliate of Millipore, Billerica, MA, USA)), anti-p85PI3K (rabbit polyclonal, UBI), anti-P-Serine (rabbit polyclonal, Zymed, San Francisco, CA, USA), antiErk 1/2 (rabbit polyclonal, Santa Cruz, Santa Cruz, CA, USA), anti-P-Erk 1/2 (mouse monoclonal, Santa Cruz), anti-P-Akt Ser 473 (rabbit polyclonal, Cell Signaling, Beverly, MA, USA), anti-Akt (rabbit polyclonal, Cell Signaling), anti-P-Gsk Ser 21/9(rabbit polyclonal, Cell signaling), anti-GSKa/b (mouse monoclonal, UBI). The anti-flag antibody was the mouse monoclonal Sigma M2 antibody.
Immunoprecipitation Total extracts were prepared by lysing the cells on ice 5 min with 50 mM Tris-HCl pH 7.4, 1% Nonidet NP-40, 100 mM NaCl, 2 mM EDTA 50 mM NaF, 0.1 mM NaVO 3 1 mM bglycerophosphate, 2.5 mM sodium pyrophosphate and a protease inhibitor cocktail. Cell lysates (2 mg/ml) were incubated with 4 mg of antibody/0.5-1 mg of protein at 41C in gentle rock agitation 15 h. At the end of incubation, 20 ml of A/G plus were added to samples and the immunoprecipitates were collected by centrifugation. SDS-PAGE and immunoblots were performed as previously described (Feliciello et al., 2000) .
Anoikis
At 48 h after transfection, the cells were collected and maintained in suspension on dishes covered with a thin layer of 2% agarose. Cells were plated in medium containing 0.1% serum with or without 200 mM CPT-cAMP (Sigma) for 5 h. At the end of incubation, the cells were collected, washed twice with phosphate-buffered saline (PBS) and incubated 5 min with propidium iodide and analysed by FACS.
Analysis of DNA content and 5
0 -bromo-2 0 -deoxyuridine (BrdU) incorporation 2 Â 10 6 transfected cells (48 h after transfection) were plated in 100 mm dishes and grown in low serum (0.5% fetal bovine serum) for 18 h in the presence or in absence of 50 mM 8-Cl cAMP. Cells were labelled for 30 min with BrdU to a final concentration of 20 mg/ml and harvested at 0, 90 and 270 min. After treatment, the cells were fixed in ice-cold 70% ethanol for 4 h at þ 41C and washed three times in PBS. Cells were resuspended in 0.25 ml of 1 N HCl and maintained 20 min at room temperature. After acidic denaturation of DNA, the cells were washed two times in phosphate/citric buffer (0.2 M Na 2 HPO 4 ; pH 7.4). BrdU incorporation was revealed by anti-BrdU-FITC (Becton Dickinson, Franklin Lakes, NJ USA) and then stained for 30 min at room temperature in 0.1% Triton X-100, 0.2 mg/ml DNase-free RnaseA, 20 mg/ml propidium iodide. Fluorescence was determined by using the FACScan Flow Cytometer (Becton Dickinson). Experiments were performed in triplicate. The data were acquired and analysed by CELLQuest software (Becton Dickinson) and by Cell Fit Cell-Cycle Analysis Version 2 for bivariate analysis of DNA content versus BrdU incorporation.
In vitro phosphorylation HeLa cells were transiently transfected with p85a PI3K -flag and p85A. At 48 h after transfection, cell lysates were immunoprecipitated with non-immune IgG or anti-flag antibody 15 h at 41C. Protein A/G bound immunoprecipitates were washed twice with lysis buffer and finally with kinase buffer (N-2-hydroxyethylpiperazine-N 0 -2-ethane sulfonic acid (HEPES) 20 mM, MgCl 2 10 mM, pH 7.4). The washed immunoprecipitates were treated with 0.4 mg of partly purified catalytic subunit of protein kinase A. Each aliquot was incubated in a final volume of 30 ml of kinase buffer containing 10 À5 M cAMP, 100 mM ATP and 10 mCi[g 32 P-ATP] for 30 min at 301C. The reaction was terminated by adding 2 Â Laemmli buffer.
Lipid kinase assay
Lipid kinase activity was determined as described by Maier et al. (1999) . Briefly, the assays were carried out in a final volume of 50 ml containing 0.1% bovine serum albumin, 1 mM EGTA (ethylene glycol-bis(b-aminoethyl ether)-N,N,N',N',-tetraacetic acid), 120 mM NaCl, 40 mM HEPES, pH 7.4, 1 mM dithiothreitol, 1 mM glycerophosphate, 7 mM MgCl 2 (buffer E). Lipid vesicles (30 ml containing 320 mM phosphatidylethanolamine, 300 mM phosphatidylserine, 140 mM phosphatidylcholine, 30 mM sphingomyelin, supplemented with 40 mM PI-4,5-P2 in buffer E) were sonicated 1 h and incubated on ice 10 min. Some aliquots were preincubated with LY294002, 0.5 mM (Calbiochem (EMD Biosciences, Inc, an Affiliate of Merck KGaA, Darmstadt, Germany)) at 371C. The immunoprecipitates were added to the lipid mixture and incubated for 10 min at 41C in a final volume of 40 ml. The reaction was started by adding 40 mM ATP (1 mCi of [-32 P]ATP in 10 ml of the assay buffer at 301C. After 15 min, the reaction was stopped with ice-cold 150 ml HCl (1 N) on ice. The lipids were extracted by vortexing the samples with 500 ml of chloroform/methanol (1:1). After centrifugation the organic phase was washed twice with 200 ml of 1 N HCl. Phosphorylated lipids were separated by TLC, detected by autoradiography and quantified with Phosphor-Imager.
